ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY
申请人:Zhang Jinkun
公开号:US20140142149A1
公开(公告)日:2014-05-22
Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
A diphenylsulfonamide endothelin and angiotensin II receptor agonist to treat glomerulosclerosis
申请人:Ligand Pharmaceuticals Inc.
公开号:EP2732818A1
公开(公告)日:2014-05-21
Methods of administering and pharmaceutical compositions of a biphenyl sulphonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
A DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONISTS TO TREATGLOMERULOSCLEROSIS
申请人:Ligand Pharmaceuticals Inc.
公开号:EP3222277A1
公开(公告)日:2017-09-27
Methods of administering and pharmaceutical compositions of a biphenyl sulphonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
申请人:Ligand Pharmaceuticals, Inc.
公开号:EP3708163A1
公开(公告)日:2020-09-16
Methods of administering and pharmaceutical compositions of a biphenyl sulphonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.